UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS
Glioblastoma is the most common primary brain tumor and is considered to be among the deadliest of
human cancers. The metabolism of the cells is much higher than normal cells and, like many cancers,
represents a possible target for new drugs in cancer therapy. Our proposed research will dissect the
metabolic pathways that are abnormal in glioblastoma in a concerted effort to develop new therapies
quickly.
Choose a quarter and click "Go."
| AWARD OVERVIEW |
| Award Number |
1RC1NS070675-01 |
Funding Agency |
Department of Health and Human Services |
| Total Award Amount |
$1,000,000 |
Project Location - City |
Dallas |
| Award Date |
09/29/2009 |
Project Location - State |
TX |
| Project Status |
Completed |
Project Location - Zip |
75390-9020
|
| Jobs Reported |
0.00 |
Congressional District |
30 |
| Project Location - Country |
US |
|
|
Recipient Information
(Grants)
| Recipient Information (Grants) |
|
Recipient Name
|
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS |
| Recipient DUNS Number |
800771545
|
| Recipient Address |
5323 HARRY HINES BLVD |
| Recipient City |
DALLAS |
| Recipient State |
Texas |
| Recipient Zip |
75390-7208 |
| Recipient Congressional District |
30 |
| Recipient Country |
USA |
Required to Report Top 5
Highly Compensated Officials |
No |
Projects and Jobs Information
| Projects and Jobs Information |
| Project Title |
Genotype and Metabolic Phenotype in Glioblastoma-ARRA Stimulus Challenge Grant |
| Project Status |
Completed |
| Final Project Report Submitted |
Yes |
| Project Activities Description |
Cancer Research |
| Quarterly Activities/Project Description |
The final Total Federal Amount of ARRA Expenditure for this project is less than the Award Amount. The project was completed under budget. No more funds will be expended on this project.In the past quarter we have made significant progress in Aim 1, defining the metabolic phenotype of glioblastoma in our human orthotopic mouse model by 13C NMR spectral analysis. We have completed the analysis of the first cohort of mice infused with [U-13C]glucose, half of which were EGFR amplified and half which were WT EGFR. In preliminary analysis, there does not appear to be a difference between EGFR amp vs WT, both showing robust citric acid cycle activity and no clear evidence of increased flux through the pentose phosphate pathway. The additional cohorts are ongoing. In Aim 2, defining the metabolic phenotype in glioblastoma patients, we added a step in the experimental plan. We have infused [U-13C]glucose in a 150 lb pig (under a new animal protocol, Dr. Maher, PI), and harvested multiple brain regions for 13C NMR spectral analysis. This study was done to better prepare for the human studies in terms of clarifying dose and length of infusion time of the 13C-glucose. It provided important information that has further optimized our clinical protocol. The first glioma patients are expected to be enrolled in the study this month. In addition, the correlative imaging study of pre-operative glioblastoma patients has started. We have enrolled and imaged 7 patients to date on the 7T MR who subsequently had surgery. There have been no adverse events on the scanner and the image resolution is strikingly improved compared to 3T MRI. We are now planning to use the 7T pre-operative images in the surgical navigation system for patients enrolled on the metabolism study so that the surgeon can select the most appropriate areas of tumor/surrounding brain for the NMR spectral analysis. |
| Jobs Created |
0.00 |
| Description of Jobs Created |
N/A |
Purchaser Information
(Grants)
| Purchaser Information |
| Contracting Office ID |
Not Reported |
| Contracting Office Name |
Not Available |
| Contracting Office Region |
Not Available |
| TAS Major Program |
75-0901 |
| Award Information |
| Award Date |
09/29/2009 |
| Award Number |
1RC1NS070675-01 |
| Order Number |
|
| Award Type |
Grants |
| Funding Agency ID |
75 |
| Funding Agency Name |
Department of Health and Human Services |
| Funding Office Name |
Not Available |
| Awarding Agency ID |
75 |
| Awarding Agency Name |
Department of Health and Human Services |
| Amount of Award |
$1,000,000 |
| Funds Invoiced/Received |
$997,734 |
| Expenditure Amount |
$997,734 |
| Infrastructure Expenditure Amount |
$0 |
| Infrastructure Purpose and Rationale |
Not Reported |
| Infrastructure Point of Contact Name |
Not Reported |
| Infrastructure Point of Contact Email |
Not Reported |
| Infrastructure Point of Contact Phone |
Not Reported |
| Infrastructure Point of Contact Address |
Not Reported |
| Infrastructure Point of Contact City |
Not Reported |
| Infrastructure Point of Contact State |
Not Reported |
| Infrastructure Point of Contact Zip |
Not Reported |
Product or Service Information
(Grants)
| Product or Service Information |
| Primary Activity Code |
H02.04 |
| Activity Description |
Cancer Research |
| Sub-Awards Information |
| Sub-awards to Organizations |
0 |
| Sub-award Amounts to Organizations |
$0 |
| Sub-Awards to Individuals |
0 |
| Sub-Award Amounts to Individuals |
$0 |
| Number of Sub-awards less than $25,000/award |
0 |
| Amount of Sub-awards less than $25,000/award |
$0 |
| Number of payments to vendors greater than $25,000 |
0 |
| Total Amount of payments to vendors greater than $25,000/award |
$0 |
| Number of payments to vendors less than $25,000/award |
279 |
| Total Amount of payments to vendors less than $25,000/award |
$238,937 |
| Location Information |
| Latitude, Longitude |
32º 48' 45",
-96º 50' 18" |
| Congressional District |
30 |
| Address 1 |
5323 Harry Hines |
| Address 2 |
|
| City |
Dallas |
| County |
Dallas |
| State |
TX |
| Zip |
75390-9020 |
|
|